Immunocore Holdings plc - ADR

XNAS:IMCR  
36.80
+1.00 (+2.79%)
7:51:40 PM EDT: $37.23 +0.43 (+1.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.91B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$107.75 Million
Adjusted EPS-$0.19
See more estimates
10-Day MA$37.21
50-Day MA$35.11
200-Day MA$32.84
See more pivots

Immunocore Holdings plc - ADR Stock, XNAS:IMCR

92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY
United Kingdom
Phone: +44.1235.438600
Number of Employees: 493
http://immunocore.com

Description

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX � Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.